Recognition of an option valuation loss related to stock acquisition rights
First written in FY2020. . Latest entry: FY2022-Q2.
No other company in this theme has enough history to compare yet.
- FY2022-Q2Updated option valuation lossAnnual report
「Non-operating expenses included interest expense of ¥286 million and a ¥17 million option valuation loss related to convertible bond-type bonds with stock acquisition rights.」
The company recorded a ¥17 million option valuation loss related to convertible bond-type bonds with stock acquisition rights. - FY2022-Q1Updated option valuation lossAnnual report
「Non-operating expenses included interest expense of ¥143 million and a ¥16 million option valuation loss related to convertible bond-type bonds with stock acquisition rights. As a result, quarterly net income before income taxes was ¥542 million.」
The company recorded a ¥16 million option valuation loss related to convertible bond-type bonds with stock acquisition rights. - FY2021Updated the option valuation loss with full-year resultsAnnual report
「Non-operating expenses totaled ¥5,972 million, mainly comprising interest expense of ¥1,472 million and an option valuation loss of ¥4,491 million.」
The full-year option valuation loss was ¥4,491 million, up from ¥2,766 million in the previous year. - FY2021-Q3Updated option valuation lossAnnual report
「Non-operating expenses included interest expense of ¥1,220 million and a ¥3,104 million option valuation loss related to convertible bond-type bonds with stock acquisition rights. As a result, the quarterly net loss before income taxes was ¥3,801 million.」
The company recorded a ¥3,104 million option valuation loss related to convertible bond-type bonds with stock acquisition rights. - FY2020First statedAnnual report
「Non-operating expenses totaled ¥5,398 million, mainly comprising interest expense of ¥1,999 million, an option valuation loss of ¥2,766 million and foreign exchange losses of ¥570 million.」
The company recorded a ¥2,766 million option valuation loss related to stock acquisition rights with clauses for adjustments to the exercise price under non-operating expenses.